Shionogi & Co., Ltd.

Equities

4507

JP3347200002

Pharmaceuticals

Delayed Japan Exchange 07:00:00 18/07/2024 BST 5-day change 1st Jan Change
6,717 JPY +1.39% Intraday chart for Shionogi & Co., Ltd. +0.40% -1.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Japanese Shares Close Higher as Officials Address Yen Volatility Concerns MT
Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan MT
Shionogi & Co. to Dispose of 450 Million Yen Worth of Shares as Restricted Stock Compensation MT
Japan's Nikkei little changed ahead of key US data, central bank meetings RE
Japan's Nikkei edges down ahead of key US data, central bank meetings RE
Japan's Nikkei drifts sideways as more earnings, US CPI awaited RE
Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial RE
Akili, Inc. Announces an Amendment to its Strategic Distribution Agreement with Shionogi & Co., Ltd CI
Shionogi & Co., Ltd. Revises Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares MT
Shionogi & Co., Ltd. Announces New Data from the European Real-World Evidence Study of Fetroja®/F etcroja® (cefiderocol) CI
Shionogi Completes Up to 75 Billion Yen Share Buyback MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023. CI
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million. CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial MT
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen MT
GSK says ViiV's cabotegravir study supports longer HIV dose interval AN
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir MT
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs RE
GSK's new HIV drug formula could support longer dosing intervals (March 4) RE
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval RE
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings RE
FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
Chart Shionogi & Co., Ltd.
More charts
Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products: - prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.; - OTC products: analgesic products, vitamins and tonics, etc.; - diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
6,625 JPY
Average target price
7,594 JPY
Spread / Average Target
+14.62%
Consensus
  1. Stock Market
  2. Equities
  3. 4507 Stock
  4. News Shionogi & Co., Ltd.
  5. Shionogi & Co Introduces Covgoze Vaccine for Covid-19 in Japan